found that 23 out of 475 (4.8%) AML patients bear mutated IKZF1, and delineated three clusters of IKZF-mutated as: N159S (40%), co-occurring CEBPA mutations (43%), and others (17%) (102). This evidence concerns the gene CEBPA and acute myeloid leukemia.